Main Article Content
Coronavirus (COVID-19) is an important public health emergency of international concern. Firstly COVID-19 was isolated from Wuhan market in China at 7 Jan. 2020. As of this time, there is no known effective pharmaceutical treatment; although it is much needed for patient contracting severs form of the disease. This virus causes respiratory infection in human including sneezing, coughing, cold and pneumonia while in animal it causes diarrhea and upper respiratory diseases. COVID-19 is transmitted human to human or human to animal via airborne droplets. This disease can be diagnosis on the basis of travel history from infected areas, common symptom or by laboratory confirmations. WHO advised to avoid public place, close contact to Coronavirus infected persons, wearing mask, sanitizing hands and maintain social distancing for prevention. It’s also advised infected pensions keep in quarantine center for 14 days or separate from other family member to single separate room, implementation of contact, droplet precaution, and airborne precaution, keep physical distances. Some countries are also using lopinavir/ritonavir, remdesivir, chloroquine and hydroxychloroquine drugs for treatment of Coronavirus but these are not efficient in cure of this disease. The aim of the systematic review of literature is to summarize the evidence regarding COVID-19, symptoms, pathogenesis and prevention/treatment.
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel Coronavirus: Implication for virus origins and receptor binding. Lancet. 2020; 395:365-574.
Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Method Mol Biol. 2015;1282:1-23.
Kumar D, Malviya R, Kumar SP. Corona Virus: A Review of COVID-19. EJMO. 2020; 4(1):8-25.
WHO. Coronavirus never before seen in humans is the cause of SARS-update 31. Geneva: The Organization; 2003.
Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel Coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol; 2020.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine; 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020;87(4):281-286.
Xinhua. China’s CDC detect a large number of new coronaviruses in the South China seafood market in Wuhan; 2020.
Unhale SS, Ansar QB, Sanao S, Thakhre S, Wadatkar S, Bairagi R, Sagrule S, Biyani KR. A Review on Coronavirus (COVID-19). WJPLS. 2020;6(4):109-115.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Feature, Evaluation and Treatment Coronavirus (COVID-19). Stat pearls Publishing, Treasure Island, FL; 2020.
Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in the USA, Lancet; 2020. (Accessed: March 21, 2020)
Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (Coronavirus disease-2019) diagnosis, treatment and prevention. EJMO. 2020;4(2): 116-125.
Hassan S, Sheikh FN, Jamal S, et al. Coronavirus (COVID-19): A review of clinical feature, diagnosis, and treatment. Cureus. 2020;12(3):e7355.
Bendix A. A day-by day breakdown of Coronavirus symptom shows how the disease, COVID-19, goes from bad to worse. Business Insider; 2020.
Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel voronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7:4.
Gupta N, Praharaj I, Bhatnagar T, Thangaraj JWV, Giri S, Chauhan H, Kulkarni S, Murhekar M, Singh S, Gangakhedkar RR, Bhargab B, ICMR COVID Team. Severe acute respiratory illness surveillance for Coronavirus disease 2019, India. Indian J Med Res. 2020; 1-5.
Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel Coronavirus indicating person-to-person transmission: A study of a family cluster. The Lancet; 2020.
Chatterjee P, Nagi N, Agarwall A, Das B, Banerjee S, Sarkar S, Gupta N, Gangakhedkar RR. The 2019 novel Coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res. 2020;1-13.
Chang D, Xu H, Rebaza A, Sharma L, Cruz CSD. Protecting health-care workers from subclinical Coronavirus infection. Lancet Respir Med. 2020;8:PE13.
Zhang T, He Y, Xu W, Ma A, Yang Y, Xu KF. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. Sci China Life Sci. 2020;63: 774-4.
Pascarella G, Strumial A, Piliego C, Bruno F, Buono RD, Costa F, Scarlata S, Agr FE. COVID-19 diagnosis and management: A comprehensive Review. JIM. 2020;1-15.
Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727-32.
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59:252-6.
Lim J, Jeon S, Shin HY et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020; 35:e79.
Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92:556-63.
Young BE, Ong AWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARSCoV-2 in Singapore. JAMA. 2020;323:1488.
Han W, Quan B, Guo Y et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92:461-3.
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382: 1787-1799.
Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020; 101615.
Vincent MJ, Bergeron E, Benjannet S et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2:69.
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006; 6:67-9.
Yan Y, Zou Z, Sun Y et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23:300-2.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-3.
Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177: 104762.
Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.
Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel voronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight CIVID-19. Int J Antimicrob Agents. 2020;55:105932.
Guo YR, Cao QD, Hong ZS et al. The origin, transmission and clinical therapies on Coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020;7:11.
Li T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2(SARS-CoV-2) infection: An operational recommendation of Peking Union Medical. College Hospital (V2.0). Emerg Microb Infect. 2020;9:582-5.